Business Club March 3rd The company that has successfully succeeded in grabbing imitation has its own uniqueness in independent innovation, but it is not an easy task to successfully market the imitation products and occupy a higher market share. More companies may The eve of grabbing imitation, or lost in the fierce market competition. More importantly, domestic pharmaceutical companies sometimes embraced them. Dozens of companies competed for one product for the first time. Even the best products and even the largest market were disrupted. The original patent manufacturers' influence still remained. How much does the company compete in the same stage and grab it?
The world’s first pharmaceutical Lipitor with annual sales of more than US$13 billion, which has been ranked as the leader in the global pharmaceutical market for several consecutive years, is about to expire on this year’s patent – ​​facing such a huge market demand space for China that specializes in the production of generic drugs. For pharmaceutical companies, how can we not be completely excited? What's more, this year and years later, there are a lot of patented drugs like Lipitor, which have expired and have sales of more than US$1 billion. This is an immense temptation, but it may also be a dangerous trap.
According to relevant information, there will be a total of US$77 billion worth of pharmaceutical patents due to expire in 2011-2015, which means that those technology leaders and domestic pharmaceutical companies specializing in featured products are expected to share a share in this feast; the next 10 During the year, the new medical reform in the United States will consume about 1 trillion US dollars, most of which are low-priced generic drugs, which means that domestic pharmaceutical companies' products face a rare opportunity to enter the regulatory market. The combined data of “77 billion yuan†and “1 trillion yuan†strongly stimulated the nerves of domestic drug companies: they must seize this opportunity.
A few years ago, such opportunities had emerged. Some companies seized the opportunity to become winners, while others had a joyous time. Has created a record of US$7 billion in annual sales of simvastatin. In 2003 and 2006, patents expired in Europe and the United States respectively. Hisun Pharmaceutical seized the opportunity before the expiration of patents for simvastatin to take the lead in copying the world’s success. The company’s revenue increased by more than 100% during the year, and its profit soared by more than 200%, which led to the explosive growth of the company’s statins. Hezheng Pharmaceutical has thus consolidated its strategy for the development of specialty APIs, and has also laid a foundation in this area. First-mover advantage and leading position. Not coincidentally, Huahai Pharmaceutical, which is also famous for its characteristic raw material medicines, received a FDA approval for the new drug application for nevirapine tablets in 2007. It became the first company in China to have passed FDA certification. The US patent for nevirapine will expire in November 2011, and Huahai’s A good day is coming.
However, the temptation itself is fraught with dangers, and the feast is very likely to evolve into a "leftover." Firms that have the strength to succeed in grabbing imitation have their own uniqueness in independent innovation, but it is difficult to successfully market the product and occupy a higher market share. More enterprises may fall into the eve of grabbing imitation, or Lost in the fierce market competition. Today's generic drugs and patented drugs have almost no difference in terms of technical standards, process requirements, performance parameters and quality indicators. Some of the domestic generic drugs are even higher than their national conditions. The feast may become a "leftover." The more important reason is that domestic pharmaceutical companies have always swarmed and swarmed. Dozens of companies have fought for a variety of products, and even the best products and even bigger markets have been disrupted. The original patent manufacturer's influence is still there - how many companies compete with each other and how much is grabbed?
The patent medicines that are due worldwide are of course a promising market. However, whether or not they can eat, how to eat, and what to eat, the pharmaceutical companies still have to make careful decisions based on the actual situation of the company itself. “All roads lead to Romeâ€, the road to success for Chinese pharmaceutical companies is not only imitation, but it is the right path to improve their independent innovation capabilities. Even if they are committed to generic drugs, the focus is on secondary development.
The world’s first pharmaceutical Lipitor with annual sales of more than US$13 billion, which has been ranked as the leader in the global pharmaceutical market for several consecutive years, is about to expire on this year’s patent – ​​facing such a huge market demand space for China that specializes in the production of generic drugs. For pharmaceutical companies, how can we not be completely excited? What's more, this year and years later, there are a lot of patented drugs like Lipitor, which have expired and have sales of more than US$1 billion. This is an immense temptation, but it may also be a dangerous trap.
According to relevant information, there will be a total of US$77 billion worth of pharmaceutical patents due to expire in 2011-2015, which means that those technology leaders and domestic pharmaceutical companies specializing in featured products are expected to share a share in this feast; the next 10 During the year, the new medical reform in the United States will consume about 1 trillion US dollars, most of which are low-priced generic drugs, which means that domestic pharmaceutical companies' products face a rare opportunity to enter the regulatory market. The combined data of “77 billion yuan†and “1 trillion yuan†strongly stimulated the nerves of domestic drug companies: they must seize this opportunity.
A few years ago, such opportunities had emerged. Some companies seized the opportunity to become winners, while others had a joyous time. Has created a record of US$7 billion in annual sales of simvastatin. In 2003 and 2006, patents expired in Europe and the United States respectively. Hisun Pharmaceutical seized the opportunity before the expiration of patents for simvastatin to take the lead in copying the world’s success. The company’s revenue increased by more than 100% during the year, and its profit soared by more than 200%, which led to the explosive growth of the company’s statins. Hezheng Pharmaceutical has thus consolidated its strategy for the development of specialty APIs, and has also laid a foundation in this area. First-mover advantage and leading position. Not coincidentally, Huahai Pharmaceutical, which is also famous for its characteristic raw material medicines, received a FDA approval for the new drug application for nevirapine tablets in 2007. It became the first company in China to have passed FDA certification. The US patent for nevirapine will expire in November 2011, and Huahai’s A good day is coming.
However, the temptation itself is fraught with dangers, and the feast is very likely to evolve into a "leftover." Firms that have the strength to succeed in grabbing imitation have their own uniqueness in independent innovation, but it is difficult to successfully market the product and occupy a higher market share. More enterprises may fall into the eve of grabbing imitation, or Lost in the fierce market competition. Today's generic drugs and patented drugs have almost no difference in terms of technical standards, process requirements, performance parameters and quality indicators. Some of the domestic generic drugs are even higher than their national conditions. The feast may become a "leftover." The more important reason is that domestic pharmaceutical companies have always swarmed and swarmed. Dozens of companies have fought for a variety of products, and even the best products and even bigger markets have been disrupted. The original patent manufacturer's influence is still there - how many companies compete with each other and how much is grabbed?
The patent medicines that are due worldwide are of course a promising market. However, whether or not they can eat, how to eat, and what to eat, the pharmaceutical companies still have to make careful decisions based on the actual situation of the company itself. “All roads lead to Romeâ€, the road to success for Chinese pharmaceutical companies is not only imitation, but it is the right path to improve their independent innovation capabilities. Even if they are committed to generic drugs, the focus is on secondary development.
Wheat Brusher,Wheat Brusher for Flour Mill,Wheat Brusher for Flour Milling Plant,Wheat Brusher for Grain
HEBEI PINGLE FLOUR MACHINERY GROUP CO., LTD , https://www.plrollermill.com